TinyGemsBreaks – Tonix Pharmaceuticals Holding Corp. (NASDAQ: TNXP) Reports Publication of TONMYA Pharmacokinetic Study in Peer-Reviewed Journal
Tonix Pharmaceuticals (NASDAQ: TNXP), a commercial-stage biotechnology company, announced the publication of a peer-reviewed study detailing the steady-state pharmacokinetic properties of TNX-102 SL, the sublingual formulation of cyclobenzaprine HCl marketed as TONMYA(R), in Clinical Pharmacology in Drug Development. The study, conducted in 60 healthy volunteers, demonstrated that the sublingual formulation achieves faster absorption, earlier peak plasma concentration and higher dose-normalized bioavailability compared to oral extended-release cyclobenzaprine, supporting its use for long-term bedtime dosing to target nonrestorative sleep in fibromyalgia, reduce pain and improve related symptoms. To view the full press release, visit https://ibn.fm/AX1hL Tonix Pharmaceuticals Holding Corp. Tonix Pharmaceuticals is…

